Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.69 -0.50 (-0.39%)
Streaming Delayed Price Updated: 3:21 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
From Merck & Co., Inc.
Via Business Wire
Smart Money Is Betting Big In MRK Options
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Market Analysis: Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
The Reserve Bank Of South Africa Kept The Rate At 8.25%
The Reserve Bank of South Africa unanimously decided to keep the key repo rate at 8.25%, marking the fifth consecutive meeting at 2009 levels, as expected. 
Via Talk Markets
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma, underscoring a commitment to advancing innovative therapies. 
Via Benzinga
Exposures Product Safety
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients. 
Via Benzinga
Topics Stocks
Exposures US Equities
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April.... 
Via Benzinga
Exposures Product Safety
US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead
Bargain hunters may flock to the market on Wednesday following three consecutive sessions of losses. 
Via Benzinga
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
From Merck & Co., Inc.
Via Business Wire
Merck's Cardiovascular 'Renaissance' Is Here With The First Approval Of A $10 Billion Franchise
The FDA signed off on Winrevair, a treatment for pulmonary arterial hypertension. 
Via Investor's Business Daily
Exposures Product Safety
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in... 
Via Benzinga
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression. 
Via Benzinga
Bull Market and Beyond: 2 Stocks to Buy and Hold Forever
These stocks have been providing excellent returns for a long time. 
Via The Motley Fool
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine
Merck's Phase 3 data on V116, a 21-valent pneumococcal conjugate vaccine for adults, show promising immunogenicity across diverse populations, including those at risk. 
Via Benzinga
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
From Merck & Co., Inc.
Via Business Wire
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity... 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, March 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of March 11-15, 2024. 
Via Talk Markets
Newly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival
Merck's Keytruda in combination with chemoradiotherapy achieves significant improvement in overall survival for newly diagnosed high-risk locally advanced cervical cancer patients. Keytruda is the... 
Via Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
7 Dow Darlings for Investors to Buy for March Market Madness
These 7 Dow stocks are better positioned than the other 23 within the index making them strong buy considerations. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors. 
Via InvestorPlace
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.